LS
LSTA.US Lisata Therapeutics Inc.
- Market cap
- USD 11.8M
- P/E
- -
- P/B
- 1.63x
- ROE
- -247.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LSTA.US undervalued?
Graham numberThe Graham number of Lisata Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lisata Therapeutics Inc. fundamental analysis
No fundamental analysis for Lisata Therapeutics Inc. yet.
Lisata Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of …
Full company profileLisata Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lisata Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 35.3M | - | 0.00 | 0.00 | 0.00 | 0.00 | 121M | 0.00 | 1.00M | 170K | 0.00 |
| Gross Profit | 4.15M | -372K | -225K | -65.0K | -63.0K | -55.0K | 63.8M | -189K | 1.00M | 24.0K | - |
| Operating Income | -31.3M | -27.6M | -17.0M | -20.1M | -19.1M | -29.1M | -57.6M | -25.7M | -22.4M | -18.2M | -25.3M |
| EBITDA | -29.0M | -27.2M | -16.8M | -20.0M | -19.1M | -28.9M | -56.6M | -23.0M | -20.6M | -17.4M | -25.2M |
| Net Income | -32.7M | 23.0M | -16.2M | -20.1M | -8.15M | -27.5M | -54.2M | -20.8M | -20.0M | -16.6M | -18.9M |
| EPS | -75 | 38 | -25 | -29 | -7.92 | -7.45 | -10 | -2.58 | -2.40 | -1.91 | -2.04 |
| Balance Sheet | |||||||||||
| Total Assets | 51.8M | 63.4M | 44.6M | 27.2M | 36.0M | 97.0M | 73.0M | 54.7M | 35.0M | 17.7M | 648M |
| Total Liabilities | 47.8M | 13.2M | 7.13M | 6.60M | 3.76M | 5.01M | 6.71M | 6.80M | 5.69M | 3.14M | 56.8M |
| Shareholders' Equity | 4.88M | 50.5M | 37.7M | 20.8M | 32.5M | 92.3M | 66.6M | 48.1M | 29.6M | 14.9M | 7.64M |
| Cash & Short-term Investments | 14.7M | 55.1M | 43.1M | 25.2M | 34.6M | 95.0M | 69.2M | 50.5M | 31.2M | 16.0M | 283M |
| Total Debt | 6.79M | 159K | - | 978K | 624K | 714K | 485K | 168K | 137K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -23.7M | -20.9M | -20.0M | -18.9M | -8.82M | -22.2M | -21.2M | -20.0M | -19.4M | -15.9M | -24.6M |
| Capital Expenditure | 2.85M | 135K | 134K | 20.0K | 20.0K | 60.0K | 285K | 0.00 | 0.00 | 28.0K | 0.00 |
| Free Cash Flow | -26.5M | -21.0M | -20.1M | -18.9M | -8.84M | -22.3M | -21.5M | -20.0M | -19.4M | -16.0M | -24.6M |
| Ratios | |||||||||||
| ROE | -668.6% | 45.5% | -42.9% | -96.6% | -25.1% | -29.8% | -81.4% | -43.3% | -67.6% | -111.7% | -247.8% |
| ROA | -63.0% | 36.3% | -36.3% | -74.0% | -22.6% | -28.3% | -74.2% | -38.1% | -57.1% | -93.5% | -2.9% |
| Net Profit Margin | -92.6% | - | - | - | - | - | -44.7% | - | -1,998.5% | -9,756.5% | - |
| Debt to Equity | 1.39x | 0.00x | - | 0.05x | 0.02x | 0.01x | 0.01x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lisata Therapeutics Inc. dividends
Lisata Therapeutics Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Sep 15, 2022.
Who owns Lisata Therapeutics Inc.
- Insiders 20.64%
- Institutions 13.80%
- Public & others 65.56%
- Shares outstanding 10.8M
- Free float 6.91M
Top funds holding LSTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 191K | 2.17% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 38.0K | 0.43% | -0.21% | Sep 2026 |
| Fidelity Series Total Market Index | 10.4K | 0.12% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 7.02K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 4.43K | 0.05% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 4.38K | 0.05% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.03K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 100.00 | 0.00% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 1 I | 8.00 | 0.00% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 8.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding LSTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 279K | 2.58% | +2.58% | Jun 2026 |
| Yakira Capital Management, Inc. | 139K | 1.28% | 0.00% | Jun 2026 |
| Css LLC | 110K | 1.02% | +78.39% | Jun 2026 |
| Deltec Asset Management LLC | 83.2K | 0.77% | -7.56% | Jun 2026 |
| Geode Capital Management, LLC | 72.6K | 0.67% | +2.46% | Jun 2026 |
| Virtu Financial LLC | 58.8K | 0.54% | +39.25% | Jun 2026 |
| BlackRock Inc | 54.9K | 0.51% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 49.0K | 0.45% | +40.23% | Jun 2026 |
| State Street Corp | 25.3K | 0.23% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 18.7K | 0.17% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 15.5K | 0.14% | -31.43% | Jun 2026 |
| Northern Trust Corp | 15.5K | 0.14% | +51.29% | Jun 2026 |
| JBF Capital, Inc. | 14.3K | 0.13% | +8.41% | Jun 2026 |
| HPM Partners LLC | 12.2K | 0.11% | 0.00% | Jun 2026 |
| Bank of America Corp | 10.4K | 0.10% | 0.00% | Jun 2026 |
| HighTower Advisors, LLC | 10.0K | 0.09% | 0.00% | Jun 2026 |
| International Assets Investment Management, LLC | 5.00K | 0.05% | 0.00% | Jun 2026 |
| Founders Capital Management Inc | 1.67K | 0.02% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 1.03K | 0.01% | 0.00% | Jun 2026 |
| Connective Capital Management LLC | 1.02K | 0.01% | 0.00% | Jun 2026 |
Lisata Therapeutics Inc. company profile
- Company name
- Lisata Therapeutics Inc.
- Ticker
- LSTA.US
- Exchange
- USA Stocks
- Listed since
- Mar 1, 1999
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Fiscal year end
- December
- Address
- 110 Allen Road, Basking Ridge, NJ, United States, 07920
- Phone
- 908 842 0100
- Website
- lisata.com
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics Inc. management
4- Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.CEO & Director · born 1957
- Mr. James NiscoSVP of Finance and Treasury & Chief Accounting Officer · born 1971
- Dr. Joshua Lehrer-Graiwer FACC, M.D.President & COO · born 1974
- Mr. Tariq ImamHead of Human Resources, Senior VP of Business Development & Operations and General Counsel · born 1983